Triple Analysis: Lung Cancer, Prostate Cancer and Peptides

NEW YORK, Nov. 17, 2011 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

Triple Analysis: Lung Cancer, Prostate Cancer and Peptides

http://www.reportlinker.com/p0284633/Triple-Analysis-Lung-Cancer-Prostate-Cancer-and-Peptides.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Prostate Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lung Cancer

The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and three subindications of lung cancer.

This part is based on the following publication:

Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

Part II: Prostate Cancer

The prostate cancer report part comprises defined and up to date development strategies for 346 prostate cancer drugs within the portfolio of 198 investigators, from Ceased to Marketed. This report part extensively analyses 202 identified targets of prostate cancer drugs, organized into 187 drug target strategies, and assesses them in prostate cancer.

This part is based on the following publication:

A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market

Part III: Peptides

The cancer peptide drug report part comprises defined and up to date development strategies for 152 peptide drugs in oncology within the portfolio of 104 companies world-wide, from Ceased to Marketed. The report extensively analyses their 123 identified drug targets, organized into 103 drug target strategies, and assesses them in 56 cancer indications.

This part is based on the following publication:

Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lung Cancer

5.1 The Scope of this Report 31

6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (241 Drug Targets) 35-526

7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target Strategies and 416 Lung Cancer Drugs) 527-817

8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy (8 Compound Strategies) 818-870

9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of Lung Cancer) 871-898

10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator (218 Companies) 899-1299

11 Disclaimer 1300

12 Drug Index 1301

13 Company Index 1314

Figures: Includes 7 Figures

Tables: Includes 284 Tables

Total Number of Pages: 1323

Part II: Prostate Cancer

5.1 The Scope of this Report 28

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (202 Drug Targets) 32-383

7 Emerging New Products to Established Ones: Drug Target Strategies by their Highest Stage of Development in the Prostate Cancer Pipeline (187 Drug Target Strategies and 346 Drugs) 384-438

8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Different Compound Strategies) 439-485

9 Pipeline and Portfolio Planning: Competitive Benchmarking of Prostate Cancer Therapeutic Pipeline by Investigator (198 Investigators) 486-820

11 Drug Index 822

12 Company Index 831

Figures: Includes 6 Figures

Tables: Includes 257 Tables

Total Number of Pages: 838

Part III: Peptides

5.1 The Scope of this Report 26

6 Consider the Therapeutic Target Among Peptide Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (123 Drug Targets) 30-248

7 Emerging New Products to Established Ones: Drug Target Strategies of Peptide Drugs in Oncology by their Highest Stage of Development (103 Drug Targets Strategies and 152 Peptide Drugs) 249-372

8 Selecting Indication for Peptide Drugs in Oncology (56 Cancer Indications) 373-441

9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Peptide Drug Pipeline in Oncology by Investigator (104 Investigators and 152 Peptide Drugs) 442-895

10 Disclaimer 896

11 Drug Index 897

12 Company Index 902

Figures: Includes 5 Figures

Tables: Includes 207 Tables

Total Number of Pages: 906

To order this report:

: Triple Analysis: Lung Cancer, Prostate Cancer and Peptides

More  Market Research Report

Check our  Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
mail: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.